Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study
- 709 Downloads
Several studies have suggested that obesity could have a negative effect on response to anti-tumor necrosis factor α (anti-TNFα) in rheumatoid arthritis (RA). Little is known about the impact of body mass index (BMI) on other biologic agents. We aimed to evaluate the effect of BMI on response to tocilizumab (TCZ) in RA. RA patients treated with TCZ were included in this multicenter retrospective study. BMI was calculated at the initiation of treatment. After 6 months of treatment, change from baseline in DAS28, pain on a visual analog scale, erythrocyte sedimentation rate and C-reactive protein level, and tender and swollen joints were analyzed. The primary endpoint was decrease in DAS28 ≥ 1.2. Secondary outcomes were good response and remission by EULAR criteria. At baseline, among 115 RA patients included, the median (interquartile range) BMI was 25.4 (22.0–28.8) kg/m2. The number of patients with normal weight, overweight, and obesity was 53 (46 %), 37 (32 %), and 25 (22 %), respectively. Baseline characteristics did not differ between the three subgroups of BMI. The median BMI did not differ between responders and non-responders for DAS28 decrease ≥1.2 (25.7 [22.1–29.9] vs 24.9 [22.0–27.1], P = 0.38), EULAR good response (25.9 [22.8–30.0] vs 25.4 [22.0–28.4], P = 0.61), and remission (25.1 [22.5–28.6] vs 25.4 [22.0–28.9], P = 0.76). BMI did not affect the response to TCZ in RA. If confirmed, these results could be helpful for the selection of a biologic agent in obese RA patients.
KeywordsObesity Rheumatoid arthritis Tocilizumab
We thank Laura Smales for copyediting.
Compliance with ethical standards
- 1.WHO (2000) Obesity: preventing and managing the global epidemic. Tech Rep Ser 894Google Scholar
- 5.Naranjo A, Sokka T, Descalzo M, Calvo-Alén J, Hørslev-Petersen K, Luukkainen R, Combe B, Burmester G, Devlin J, Ferraccioli G et al (2008) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10:R30CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Symmons D, Bankhead C, Harrison B, Brennan P, Barrett E, Scott D, Silman A (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40:1955–1961CrossRefPubMedGoogle Scholar
- 17.Heimans L, van den Broek M, le Cessie S, Siegerink B, Riyazi N, Han KH, Kerstens PJ, Huizinga TW, Lems WF, Allaart CF (2013) Association of high body mass index with decreased treatment response to combination therapy in recent onset rheumatoid arthritis patients. Arthritis Care Res 65:1235–1242CrossRefGoogle Scholar
- 32.Stavropoulos-Kalinoglou A, Metsios G, Panoulas V, Nightingale P, Koutedakis Y, Kitas G (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitvity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14(4):R160CrossRefPubMedPubMedCentralGoogle Scholar